Claude AI's Stock Picks Turn Hedge Fund Favorites: Biotech Breakout and AI Chip Bet

Claude AI’s latest stock recommendations signal a pivotal moment across two sectors now on hedge‑fund radar.

New Front in the Chip Crunch: Memory Chip Giant

■Claude AI took a 4% stake in Micron Technology (MU), a memory‑chip leader caught in the AI‑chip supply squeeze.

■Supply constraints are inflating AI‑driven application costs by 15%‑20%, creating a pricing pressure wave across the sector.

■Hedge funds such as Point72, Viking Global, and Saturn V Capital are eyeing the chip inventory for short‑term liquidity plays.

Biotech Breakout: Pharvaris’s Upside

■Pharvaris (PHVS) has a single drug for hereditary angioedema (HAE), a rare disease that can cause life‑threatening swelling attacks.

■Valuation mirrors Chiesi’s $1.9 billion purchase of KalVista, which sold a comparable drug generating $49 million annually.

■The prevention trial, due Sept 30, is priced by the market at a 50% chance of success, implying a downside to $16; Claude AI assesses the true odds at 80%.

■Short interest remains low, ranging from 0.86% (May 31) to 1.15% (latest data), making it one of the least‑shorted mega‑cap health stocks.

Hedge Funds’ Strategic Positioning

■According to Insider Monkey, 36 funds held Pharvaris at the end of Q1, up from 35 the previous quarter.

■Notable owners include Andreas Halvorsen’s Viking Global, James Flynn’s Deerfield Management, Steve Cohen’s Point72, and Saturn V Capital.

■The funds’ stance reflects a view of Pharvaris as a high‑probability surprise given its low short interest and pending catalyst.

Markets are watching Claude AI’s dual‑sector bets closely; the memory‑chip shortage and the HAE trial catalyst could spark a fresh risk‑on/off wave. Hedge‑fund positions serve as a leading indicator of liquidity flows and may amplify volatility ahead.